Alzecure Pharma CEO Departs After Eli Lilly Deal Drives 270% Surge

Alzecure Pharma CEO Martin Jönsson steps down by mutual agreement, following a year of massive stock gains driven by a licensing deal with Eli Lilly. The departure introduces leadership uncertainty at a critical juncture as the company prepares for its next development phase. The move may signal strategic shifts or internal disagreements, though the company frames it as amicable.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works